+44 330 818 7254 Editorial
Diagnostic and complications occur obey in HIV-1-infected young people and adolescents with triple-class antiviral drugs drug-resistant viruses in Seville.
Author(s): Michael C Keefer*
Drug resistance mutations jeopardise the success of antiretroviral therapy in children infected with the human immunodeficiency virus type 1 (HIV-1). We present the virologic and clinical outcomes of the Madrid cohort of perinatally HIV-infected children and adolescents after triple-class drug-resistant mutations were chosen (TCDRM). According to IAS-USA-2013, we assigned patients with HIV-1 variants with TC-DRM to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors. From 2000 to 2011, we recovered pol sequences or resistance profiles, as well as clinical-immunologic-virologic data from the time TC-DRM was detected until December 2013. From 2000 to 2011, viruses carrying TC-DRM were found in 48 (9%) of the 534 children and adolescents studied, rising to 24.4% among the 197 with resistance data. 95.8% of them were diagnos.. View More»
DOI:
10.14303/2141-5463.2023.27